RecruitingNCT05177393
Treatment Outcomes of Esophageal Cancer
Sponsor
University of California, San Francisco
Enrollment
2,476 participants
Start Date
Feb 28, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
This study will be a carried out through a prospective observational cohort design in conjunction with researchers in the African Esophageal Cancer Consortium (AfrECC). The purpose of this research is to prospectively evaluate outcomes related to existing treatment strategies for esophageal cancer (EC) at participating sites within AfrECC.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Participants with histopathologically confirmed or presumptive clinical diagnosis of EC. For patients who do not have histopathologically confirmed disease, presumptive clinical diagnosis may be based upon barium swallow or endoscopy without biopsy.
- Age 18 years of age or older;
Exclusion Criteria1
- Unable to provide informed consent
Interventions
OTHERAssessment of patient-reported outcomes (PROs)
Questionnaires will be administered to participants
Locations(6)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05177393
Related Trials
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
NCT051871821 location
Resilience and Equity in Aging, Cancer, and Health (REACH)
NCT046742671 location
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
NCT0721770410 locations
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT0644597243 locations
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT0646994443 locations